New information about link between infusions of calcium and magnesium and colorectal cancer progression

FROM 2008 ORLANDO GI SYMPOSIUM

An independent panel of radiologists has not been able to verify an earlier concern that the use of calcium and magnesium infusions to reduce chemotherapy-caused neuropathy increased cancer progression.  Their reviews of scans from patients who received calcium and magnesium during chemotherapy and those who got a placebo found no significant relationship between the infusions and how quickly the cancer got worse.

Each scan was independently reviewed by two radiologists, who did not know the patient’s outcome.  When there was disagreement, a third radiologist also reviewed the scan.

Last June, a clinical trial looking at whether or not infusions of calcium and magnesium could reduce neuropathy from colorectal cancer chemotherapy was stopped when early information showed that those infusions might reduce chemotherapy effectiveness. At that time, the data monitoring committee recommended closing the trial because there was some evidence that the calcium/magnesium infusions led to a lowered response rate and more rapid time to treatment failure.

At that time plans were made for an independent review of cancer progression in the trial by a panel of radiologists. 

In July, the researchers leading the trial published a letter in the Journal of Clinical Oncology warning about the information and urging doctors to take care in using Ca/Mg infusions.

The clinical trial called CONcePT (Combined Oxaliplatin Neurotoxicity Prevention Trial) was testing two strategies for preventing peripheral neuropathy that is associated with oxaliplatin chemotherapy.  Since 60 percent of patients with metastatic colorectal cancer who are being treated with FOLFOX (oxaliplatin, 5FU, and leucovorin) will stop treatment before their cancer actually gets worse, often because of neuropathy, the researchers wanted to know if an intermittent use of oxaliplatin or using calcium and magnesium infusions before and after oxaliplatin would decrease neuropathy and increase time before treatment failed.

More information about the trial results will be available later this year at ASCO and the full report will be published.

Howard S. Hochster, MD presented the results of the independent radiology review at the GI Symposium.

Details about the GI Symposium presentation are on MedPage Today.

Technorati Tags: ,

Disclosure: C3 has accepted funding for projects and educational programs from sanofi-aventis in the form of charitable donations. C3 has ultimate authority over website content.

Share on FacebookTweet about this on TwitterPin on PinterestShare on Google+Email this to someone

Comments

  1. says

    To lose the weight while running we need to also concentrate on eating at
    the correct times. They are categorized as well as customized based
    on the needs of customers at most. Two groups are asked to perform specific
    exercises for a period of 6 weeks, 3 times a week.
    You can add running to your daily routine
    if you’re very serious about it, or just run a few times a week to keep your calorie consumption up. Jogging to lose weight might be a bit hard at the beginning especially if you have no prior experience.

  2. says

    Now you need to set a routine that will allow you to run at least four times a week
    for at least 30 minutes. It just releases less and
    less as you get to age 30 and above. This calorie deficit combined with the repair and growth
    process will allow you to burn fat all day long, every day.

Leave a Reply